Harry la Janssen

Harry la Janssen is a prominent academic figure at Johannes Gutenberg University Mainz, where they contribute to the Gastroenterology and Hepatology through intensive research in hepatitis B, hepatitis C, liver fibrosis, hepatocellular carcinoma, metabolic liver disease, viral hepatitis, liver cirrhosis, steatotic liver disease. A representative example of their recent contribution is the study titled "58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION", which offers critical insights into the dynamics of hepatitis B and hepatitis C. Additional work such as "86 SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS" further demonstrates their commitment to advancing knowledge in this domain.